Welcome to the third edition of the Duke Clinical Research Institute (DCRI) Neurosciences quarterly newsletter. This newsletter is designed to help you—our sponsors and colleagues—stay up to date on our exciting research news, publications, events, and faculty.

ABOUT DCRI NEUROSCIENCES MEDICINE

DCRI Neurosciences Medicine conducts psychiatry- and neurology-focused phase I–IV clinical trials. The thought leadership and guidance from our Duke University faculty, who are also practicing physicians, sets us apart. Click here to learn more about our faculty and expertise.

NEW PROGRAMS: SPRING 2018

EEG Coordinating Center Studies

DCRI’s coordinating center gathers all EEG data from sites around the world. Our faculty team of neurologists and epileptologists adjudicates and analyzes the data. We can serve as the CRO or work with your current CRO for this part of the study only. Contact Jen Hart for more information!

BRIDGE PROGRAM FOR BIOTECH COMPANIES

The BRIDGE Program pairs small biotech companies with faculty, pharmacokinetics, regulatory expertise, and a plan for clinically meaningful first-in-human studies in your requested therapeutic area. This program is best for companies finishing preclinical work to help them cross the “valley of death” from preclinical testing to clinical trials.

Contact Jen Hart, Associate Director of Business Development, for more details about how we can work with your team.

WE WANT TO HEAR FROM YOU: PARTICIPATE IN OUR POLL

Would you be interested in coming to Durham, NC, for a two-day Duke symposium that focuses on all aspects of stroke—from biomarkers to acute interventions, rehab with digital health, and payers?

Reply “yes” or “no” to Jen Hart to cast your vote!
MEET BRADLEY KOLLS MD, PHD, MMCI

Associate Professor of Neurology  
Brain Injury Translational Research Laboratories  
Vice Chair of Informatics and Telemedicine, Department of Neurology  
Assistant Chief Medical Officer for Neuroscience Network and Telemedicine  
Clinical Informatics Global Trials Lead, DCRI Neurosciences Medicine

Throughout Kolls’ career, he has focused on neurologic critical care and multimodal monitoring. His research interests include development of mouse-based models of post-traumatic epilepsy and brain monitoring in the ICU. “As a neurointensivist, I am interested in improving our ability to monitor brain function and the impact of therapy on our patients in the critical care setting. To this end, I am developing new approaches to patient monitoring that will integrate patient physiologic monitoring with brain activity recorded by electroencephalography (EEG),” said Kolls.

“On the basic science side, I am interested in the central nervous system’s response to injury. Although much attention has been focused on closed head injury as of late, stroke and brain hemorrhage are just as common in the civilian population and pose many of the same clinical challenges as traumatic brain injury. Using mouse models of clinically relevant brain injury, including models of stroke, subarachnoid hemorrhage, lobar hemorrhage, closed head injury, and penetrating brain injury, we can explore the key molecular events that lead to edema, secondary brain injury, hyper excitability and epilepsy, and other sequelae that contribute to poor patient recovery and significant morbidity following brain injury. By investigating the underlying mechanisms that contribute to these adaptive changes using electrophysiology and molecular biology approaches, we can then find ways to prevent them from becoming maladaptive and develop new therapies for our patients with head injuries,” he continued.

SPOTLIGHT ON NEUROSCIENCES MEDICINE CLINICAL OPERATIONS

Meet Lead Clinical Research Associate Katelynne Sharples

What are your top three priorities in the Neurosciences Medicine group as lead CRA?
As lead CRA, I’m the functional group lead and oversee the daily activities of the CRAs and CTAs. I also work on day-to-day deliverables for sponsors and serve as a point of escalation for any site-level questions.

What are your favorite things to do at the DCRI?
I like being involved from the beginning looking at new protocols to help our faculty and sponsors figure out the best way to operationalize trial design. I also really enjoy the depth of knowledge the DCRI has in terms of subject matter experts, and how involved they are in the trials.

Do you have any hobbies?
Yes, I’m a weightlifter!

Within Neurosciences Medicine, what types of indications are your favorite?
I really like ADHD and other cognitive disorders. They present a special challenge with their subjectivity that I find really interesting and rewarding.

Anything else you would like to add?
I just want to add that I can’t speak highly enough of Neurosciences faculty members. They are involved, invested, and make me feel truly like a part of the team.
As DCRI's Neurosciences Medicine therapeutic area grows, faculty and Business Development have prioritized establishing a presence at top neurological and psychiatric meetings around the world. This spring, the DCRI exhibited at two such conferences to demonstrate excellence in thought leadership and research: the American Academy of Neurology (AAN) conference in Boston, Massachusetts, and the World Intracranial Hemorrhage Conference (WICH) in Baltimore, Maryland. Learn more about our activities at these events.

**WHAT'S NEXT? UPCOMING CONFERENCES, MEETINGS, AND SPEAKING ENGAGEMENTS**

**European Cardiology Society – Barcelona**
August 26–30, 2017
Brad Kolls, MD—To present abstract: The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID.

**American Association of Neuromuscular & Electrodiagnostic Medicine – Phoenix**
September 13–16, 2017
Jeff Guptil, MD—Co-chair: Scientific Session, Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

**Neurocritical Care Society Meeting – Hawaii**
October 10–13, 2017
Michael Luke James, MD—To present: CN-105—a proof of concept study to evaluate the administration of CN-105 in participants with acute supratentorial intracerebral hemorrhage.

**CNS Summit – Boca Raton**
November 16–19, 2017
DCRI’s Neurosciences Team—Daniel Laskowitz, MD, Jeff Guptill, MD, Scott Kollins, PhD, Richard Keefe, PhD, and Jennifer Hart, Assistant Director, Business Development—will be in attendance.
NEW PUBLICATIONS

Jeffrey Guptill, MD, MA, MHS


Bradley Kolls, MD, PhD, MMCi


Daniel Laskowitz, MD, MHS


Daniel Laskowitz, MD, MHS (cont’d)


UPCOMING ABSTRACTS

**Jeffrey Guptill, MD, MA, MHS**


For more information, go to [dcri.org/neurosciences](http://dcri.org/neurosciences) or contact

Jennifer Hart
Assistant Director, Business Development
Neurosciences Medicine
Duke Clinical Research Institute
919-428-8101 | jennifer.d.hart@duke.edu

Twitter [https://twitter.com/dcrineuro](https://twitter.com/dcrineuro)
LinkedIn [https://www.linkedin.com/company/duke-clinical-research-institute](https://www.linkedin.com/company/duke-clinical-research-institute)